Relief Therapeutics Renews CHF 50 Million Share Subscription Facility
Relief Therapeutics Renews CHF 50 Million Share Subscription Facility
- 3-year CHF 50 million capital commitment from GEM
- Relief advances strategic transformation
- 創業板的3年期5000萬瑞士法郎資本承諾
- 救濟推動戰略轉型
GENEVA, SWITZERLAND / ACCESSWIRE / February 28, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the renewal of its CHF 50 million Share Subscription Facility (SSF) agreement with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited (GEM). This transaction underscores the ongoing commitment of GEM, the Company's largest shareholder since 2016, to continue fostering Relief's strategic and development initiatives with greater financial flexibility.
瑞士日內瓦/ACCESSWIRE/2024年2月28日/致力於爲特定特種、未滿足和罕見疾病提供創新治療選擇的生物製藥公司RELIEF THERAPEUTICS Holding SA(SIX: RLFTF)(OTCQB: RLFTY)(OTCQB: RLFTY)(Relief,或公司)今天宣佈與GEM Global Yield LLC續訂其5000萬瑞士法郎的股票認購額度(SSF)協議 SCS和創業板收益巴哈馬有限公司(GEM)。該交易凸顯了自2016年以來公司的最大股東創業板的持續承諾,即繼續以更大的財務靈活性促進Relief的戰略和發展計劃。
Relief and GEM have agreed to renew the SSF agreement for an additional three-year period. Under the terms of the agreement, Relief has the right to periodically issue and sell shares to GEM for a cumulated amount of up to CHF 50 million. GEM undertakes to subscribe to Relief ordinary shares upon Relief's issuance of a drawdown notice. Relief will control the timing and maximum amount of any drawdown and retains the right to draw down on the full commitment amount, subject to the customary terms of the SSF agreement. Future subscription prices under the SSF will correspond to 90% of the average of the closing prices on the SIX Swiss Exchange during the reference period, which corresponds to 15 trading days following Relief's draw down notice.
救濟和創業板已同意將SSF協議再延長三年。根據協議條款,Relief有權定期向創業板發行和出售股票,累計金額不超過5000萬瑞士法郎。創業板承諾在救濟發佈提款通知後認購救濟普通股。救濟將控制任何提款的時間和最大金額,並保留提取全額承諾金額的權利,但須遵守SSF協議的習慣條款。SSF下的未來認購價格將相當於SIX瑞士交易所平均收盤價的90%,參考期內相當於Relief發出提款通知後的15個交易日。
GEM also agreed to forgive an outstanding liability of CHF 1.37 million previously payable by Relief to GEM. Relief has committed to issuing GEM warrants to purchase up to 3.35 million ordinary shares at a purchase price of CHF 1.70 per share, exercisable from the issuance date, and expiring on January 20, 2027. The issuance of these warrants, as well as the ability of the Company to draw on the SSF, is contingent upon shareholder approval for a reduction in the nominal value of the Company's ordinary shares at the next general meeting.
創業板還同意免除先前通過救濟支付給創業板的137萬瑞士法郎的未清負債。Relief已承諾發行創業板認股權證,以每股1.70瑞士法郎的收購價購買多達335萬股普通股,可自發行之日起行使,並於2027年1月20日到期。這些認股權證的發行以及公司從SSF中提取資金的能力,都取決於股東在下次股東大會上批准降低公司普通股的名義價值。
"We are pleased to announce the renewal of our Share Subscription Facility with GEM, a decision that strengthens Relief's financial foundation for the next three years. GEM's CHF 50 million capital commitment reflects continued support for Relief's development plans and long-term goals," commented Michelle Lock, interim chief executive officer of Relief.
“我們很高興地宣佈,我們與創業板續訂了股票認購協議,這一決定鞏固了救濟基金未來三年的財務基礎。GEM的5000萬瑞士法郎資本承諾反映了對Relief發展計劃和長期目標的持續支持。” Relief臨時首席執行官米歇爾·洛克評論道。
Corporate update
Relief recently embarked on a transformative journey to refine its strategic direction and operational efficiency, marking a significant organization reset. In November 2023, the Company appointed Michelle Lock, a seasoned pharmaceutical executive, as its interim chief executive officer. In December 2023, Relief announced its intent to shift from a direct marketing and sales infrastructure to a partnership-based model for its commercial-stage assets and to reallocate resources towards its advancing R&D pipeline.
企業最新動態
Relief最近踏上了變革之旅,以完善其戰略方向和運營效率,這標誌着組織進行了重大重組。2023年11月,該公司任命經驗豐富的製藥業高管米歇爾·洛克爲臨時首席執行官。2023年12月,Relief宣佈打算將其商業階段資產從直接營銷和銷售基礎設施轉向基於合作伙伴關係的模式,並將資源重新分配給其不斷髮展的研發渠道。
Under Ms. Lock's guidance, Relief is actively conducting a thorough review of its strategic plans and development projects. The Company is committed to implementing a scalable, industry standard infrastructure, aimed at ensuring a sustainable path forward, enhancing shareholder value, and contributing positively to global healthcare. The Company anticipates providing a comprehensive corporate and portfolio update in the early second quarter of 2024.
在洛克女士的指導下,救濟組織正在積極對其戰略計劃和發展項目進行全面審查。公司致力於實施可擴展的行業標準基礎設施,旨在確保可持續的前進道路,提高股東價值,爲全球醫療保健做出積極貢獻。該公司預計將在2024年第二季度初提供全面的公司和投資組合更新。
ABOUT GEM
Global Emerging Markets is a $3.4 billion alternative investment group that manages a diverse set of investment vehicles and has completed over 570 transactions in 70 countries. GEM's investment vehicles provide the group and its investors with a diversified portfolio of asset classes that span the global private investing spectrum. Its family of funds and investment vehicles provides GEM and its partners with exposure to small-mid cap management buyouts, private investments in public equities (PIPEs) and select venture investments. For more information:
關於寶石
全球新興市場是一家價值34億美元的另類投資集團,管理着各種投資工具,已在70個國家完成了570多筆交易。創業板的投資工具爲該集團及其投資者提供了涵蓋全球私人投資領域的多元化資產類別組合。其基金和投資工具家族爲創業板及其合作伙伴提供了中小型股管理層收購、公開股權私人投資(PIPE)和精選風險投資的機會。欲了解更多信息:
ABOUT RELIEF THERAPEUTICS
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief's portfolio offers a balanced mix of marketed, revenue-generating products, our proprietary, globally patented Physiomimic and TEHCLO platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare metabolic disorders, rare skin diseases and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Relief's mission is to provide therapeutic relief to those suffering from rare diseases and is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Relief is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany and Monza, Italy. Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit our website or follow Relief on LinkedIn .
關於緩解療法
Relief 是一家處於商業階段的生物製藥公司,致力於推進治療模式,改善療效、安全性和便利性,以造福特定特種和罕見疾病患者的生活。Reliev的產品組合平衡地組合了已上市的創收產品、我們在全球獲得專利的Physiomic和TEHCLO平台技術,以及由風險緩解資產組成的有針對性的臨床開發管線,這些資產側重於三個核心治療領域:罕見代謝疾病、罕見皮膚病和罕見呼吸道疾病。此外,Relief正在通過許可和分銷合作伙伴將幾種傳統產品商業化。Relief的使命是爲罕見疾病患者提供治療性救濟,由一支由知名的、經驗豐富的生物製藥行業領導者組成的具有廣泛研究、開發和罕見病專業知識的國際團隊正在推動這一使命。Relief總部設在日內瓦,在瑞士巴萊爾納、德國美因河畔奧芬巴赫和意大利蒙扎設有辦事處。救濟在瑞士證券交易所上市,股票代碼爲RLF,並在美國的OTCQB上市,股票代碼爲RLFTF和RLFTY。欲了解更多信息,請訪問我們的網站或在 LinkedIn 上關注 Relief。
CONTACT :
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
聯繫 :
救濟療法控股有限公司
傑里米·梅寧
首席財務官
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, including its ability to achieve its corporate, development and commercial goals, and other factors which could cause the actual results, financial condition, performance or achievements of Relief to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A number of factors, including those described in Relief's filings with the SIX Swiss Exchange and the U.S. Securities and Exchange Commission (SEC), could adversely affect Relief. Copies of Relief's filings with the SEC are available on the SEC EDGAR database at www.sec.gov. Relief does not undertake any obligation to update the information contained herein, which speaks only as of this date.
免責聲明
本新聞稿包含前瞻性陳述。前瞻性陳述涉及已知和未知的風險、不確定性,包括其實現公司、發展和商業目標的能力,以及其他可能導致救濟基金的實際業績、財務狀況、業績或成就與此類前瞻性陳述所表達或暗示的任何未來業績、業績或成就存在重大差異的因素。許多因素,包括救濟基金向瑞士證券交易所和美國證券交易委員會(SEC)提交的文件中描述的因素,可能會對救濟產生不利影響。救濟組織向美國證券交易委員會提交的文件副本可在美國證券交易委員會EDGAR數據庫www.sec.gov上查閱。Relief不承擔任何義務更新此處包含的信息,這些信息僅涉及截至該日期。
SOURCE: RELIEF THERAPEUTICS Holding SA
來源:救濟療法控股有限公司
譯文內容由第三人軟體翻譯。